Literature DB >> 10997470

Embolotherapy for venous impotence: use of ethanol.

M Nakata1, S Takashima, T Kaminou, Y Koda, A Morimoto, M Hamuro, T Matsuoka, R Yasumoto, K Nakamura, R Yamada.   

Abstract

PURPOSE: To evaluate the usefulness of embolotherapy with ethanol for the treatment of venous impotence.
MATERIALS AND METHODS: Twenty-three patients with venous impotence underwent embolotherapy. The diagnosis of venous impotence was made by means of pharmacocavernosometry and cavernosography. After exposure of the deep dorsal penile vein, a intravenous catheter was inserted directly into the deep dorsal penile vein and advanced into just front of the preprostatic plexus. Fifty percent ethanol was injected through the catheter and the endpoint of the procedure was determined based on results of venography immediately after injection. The procedure was finished when lack of venous leakage was confirmed.
RESULTS: In all patients, the deep dorsal penile vein was successfully exposed surgically, the sclerosing agent successfully injected, and the endpoint successfully achieved. Immediate clinical therapeutic effect (restoration of erection) was obtained in 20 cases (87%). No severe complications were observed during or after the procedure. The follow-up period was 6-50 months. Long-term therapeutic effect was confirmed for 18 of 23 patients (78%).
CONCLUSION: The authors' findings suggest that this treatment had satisfactory short-term and long-term clinical results and that longer follow-up is necessary to confirm its safety.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10997470     DOI: 10.1016/s1051-0443(07)61338-4

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  1 in total

1.  Dynamic infusion cavernosometry and cavernosography for classifying venous erectile dysfunction and its significance for individual treatment.

Authors:  Qing-Qiang Gao; Jian-Huai Chen; Yun Chen; Tao Song; Yu-Tian Dai
Journal:  Chin Med J (Engl)       Date:  2019-02       Impact factor: 2.628

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.